Other substances

Zanamivir

An acetamide neuraminidase inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
9
 AI-suggested references
0
 Clinical trials

General information

Zanamivir on PubChem

Marketed as

RELENZA

 

Structure image - Zanamivir

CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)O)C(=O)O)N=C(N)N

Supporting references

Link Tested on Impact factor Notes Publication date
MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs
3CLpro Small molecule In silico 		in silico 8.99

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Oct/20/2020

AI-suggested references

Link Publication date
Quantitative structure-activity relationships, molecular docking and molecular dynamics simulations reveal drug repurposing candidates as potent SARS-CoV-2 main protease inhibitors.
Jan/19/2022
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
Mar/30/2021
An investigation for the interaction of gamma oryzanol with the Mpro of SARS-CoV-2 to combat COVID-19: DFT, molecular docking, ADME and molecular dynamics simulations.
Jan/22/2022
A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
Apr/12/2020
All-cause mortality among patients treated with repurposed antivirals and antibiotics for COVID-19 in Mexico City: A real-world observational study
Jun/24/2021
Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children
Aug/02/2021
Probing antiviral drugs against SARS-CoV-2 through virus-drug association prediction based on the KATZ method
Mar/11/2022
Evaluation of drug repositioning by molecular docking of pharmaceutical resources available in the Brazilian healthcare system against SARS-CoV-2
Feb/19/2021
Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease
Jun/29/2020
Export (.csv)